España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Lobe Sciences
LOBEF
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.012500
-0.0024
-16.11%
At close: -
$0.014900
0.0024
19.20%
After Hours: Oct 29, 9:08 AM EDT
Get Report
Comment
Lobe Sciences (LOBEF) Forecast
News
Earnings
Lobe Sciences (LOBEF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Lobe Sciences (OTC:LOBEF) Stock
Lobe Sciences Stock (OTC: LOBEF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, January 15, 2024
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Lara Goldstein
Tuesday, July 04, 2023
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein
Wednesday, June 28, 2023
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lara Goldstein
Monday, April 24, 2023
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Lara Goldstein
Thursday, April 20, 2023
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
Lara Goldstein
Tuesday, February 28, 2023
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
Richard Dal Monte
-
Sponsored
Friday, January 27, 2023
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
Lara Goldstein
Tuesday, November 22, 2022
Lobe Sciences Hopes To Move Novel Psilocin Drug Compounds Quickly Through The FDA Funnel
The Dales Report
Friday, October 14, 2022
Proprietary Psychedelic Readies For Trials Targeting Neurologic And Brain Disease
Lara Goldstein
Thursday, September 01, 2022
Psychedelics Funding At Its Best: $1.5M Destined To Psilocin Clinical Trials In Australia
Lara Goldstein
Wednesday, August 10, 2022
Lobe Sciences Signs Exclusive Deal For Psilocin Clinical Trials In Australia
Lara Goldstein
Tuesday, July 19, 2022
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Lara Goldstein
Wednesday, June 15, 2022
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Natan Ponieman
Wednesday, June 08, 2022
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
Lara Goldstein
